AstraZeneca's newly developed weight-loss pill, elecoglipron, has shown promising results in a phase 2 trial, demonstrating weight loss comparable to other oral GLP-1 medications. The trial, published in the Lancet, involved 310 participants and reported average weight reductions of up to 10.5% at 26 weeks and 11.8% at 36 weeks for the highest-dose group. Side effects were similar to those of existing GLP-1 drugs, with nausea being the most frequently reported issue. Marie Spreckley, a weight management researcher at the University of Cambridge, noted that while the results are encouraging, larger and longer phase 3 trials are needed to assess the durability of these effects and the pill's long-term safety. AstraZeneca's entry into the weight-loss market could be significant, especially as it competes with established players like Novo Nordisk and Eli Lilly, both of which have already released oral versions of their successful GLP-1 drugs. Eli Lilly's oral Mounjaro was approved in the U.S. in April, while Novo Nordisk's Wegovy has also received authorization in the U.S. and the European Union.